| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | NEUTRAL | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 16.89▼ | 16.89▼ | 16.89▼ | 17.02▼ | 14.81▲ |
| MA10 | 17.28▼ | 17.28▼ | 17.22▼ | 15.91▲ | 15.66▲ |
| MA20 | 16.84▼ | 16.64▼ | 16.31▲ | 15.31▲ | 17.91▼ |
| MA50 | 15.65▲ | 15.66▲ | 15.45▲ | 16.07▲ | 14.47▲ |
| MA100 | 15.12▲ | 15.11▲ | 15.02▲ | 18.06▼ | 10.71▲ |
| MA200 | 15.27▲ | 16.05▲ | 17.05▼ | 15.06▲ | 9.34▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.148▼ | -0.118▼ | -0.079▼ | 0.334▲ | -0.616▼ |
| RSI | 48.132▼ | 49.713▼ | 51.372▲ | 53.068▲ | 51.543▲ |
| STOCH | 30.059 | 33.880 | 38.457 | 80.425▲ | 21.211 |
| WILL %R | -100.000▼ | -100.000▼ | -58.303 | -39.588 | -71.376 |
| CCI | -134.042▼ | -125.641▼ | -81.448 | 53.813 | -25.585 |
|
Thursday, November 12, 2026 01:48 AM
Eli Lilly has secured Chinese regulatory approval for its oral GLP-1 weight-loss drug, orforglipron, becoming the first drugmaker to receive clearance for a GLP-1 we ...
|
|
Wednesday, November 11, 2026 07:15 PM
Novo Nordisk lived up to expectations for its Wegovy pill in the third quarter, but it still has more work ahead.
|
|
Sunday, November 08, 2026 02:04 PM
A 6% post-earnings surge in Novo Nordisk (NYSE: NVO) shares has reignited investor optimism around the Denmark-based pharmaceutical giant after a prolonged ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 13/11/26 | 16.37 | 16.37 | 16.37 | 16.37 | 60,336 |
| 12/11/26 | 18.10 | 18.10 | 16.50 | 16.55 | 67,977 |
| 11/11/26 | 17.38 | 17.99 | 17.20 | 17.99 | 94,914 |
| 10/11/26 | 16.83 | 17.35 | 16.44 | 17.32 | 88,831 |
| 09/11/26 | 15.80 | 16.905 | 15.24 | 16.85 | 142,196 |
| 06/11/26 | 13.86 | 15.25 | 13.86 | 15.18 | 52,024 |
| 05/11/26 | 15.94 | 16.07 | 13.73 | 13.73 | 91,900 |
| 04/11/26 | 15.55 | 15.79 | 14.73 | 15.60 | 35,100 |
| 03/11/26 | 14.23 | 15.42 | 14.00 | 15.06 | 125,700 |
| 02/11/26 | 14.79 | 15.20 | 14.37 | 14.48 | 76,800 |
|
|
||||
|
|
||||
|
|